Evidence map›Paper›PMID 32818920›Full record

ArticleMolecular therapy. Nucleic acids2020

Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment.

Brennon O'Callaghan, Bente Hofstra, Hillary P Handler, Holly B Kordasiewicz, Tracy Cole, Lisa Duvick, Jillian Friedrich, Orion Rainwater, Praseuth Yang, Michael Benneyworth and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Suppression of Kv3.3 channels by antisense oligonucleotides reverses biochemical effects and motor impairment in spinocerebellar ataxia type 13 mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Brennon O'CallaghanInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Bente HofstraInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Hillary P HandlerInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Graduate Program in Neuroscience, University of Minnesota, Minneapolis, MN, USA.
Holly B KordasiewiczIonis Pharmaceuticals, Carlsbad, CA, USA.
Tracy ColeIonis Pharmaceuticals, Carlsbad, CA, USA.
Lisa DuvickInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Jillian FriedrichInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Orion RainwaterInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Praseuth YangInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Michael BenneyworthDepartment of Neuroscience, University of Minnesota, Minneapolis, MN, USA.
Tessa Nichols-MeadeDepartment of Neuroscience, University of Minnesota, Minneapolis, MN, USA.
Wesley HealInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Rachel Ter HaarInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Christine HenzlerMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, USA.
Harry T OrrInstitute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. Electronic address: orrxx002@umn.edu.
University of Minnesota · USIonis Pharmaceuticals (United States) · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Predoctoral Training of NeuroscientistsT32NS105604 · NINDS · UNIVERSITY OF MINNESOTA · PI A DAVID REDISH · 2018 to 2026
$3.5M
MOLECULAR GENETICS OF THE SCA1 LOCUS ON CHROMOSOME 6PR01NS022920 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ORR, HARRY T. · 1986 to 2022
$3.2M
NCI NIH HHS P30 CA077598NINDS NIH HHS R01 NS022920NINDS NIH HHS T32 NS105604
6 · The paper itself

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a lethal, autosomal dominant neurodegenerative disease caused by a polyglutamine expansion in the ATAXIN-1 (ATXN1) protein. Preclinical studies demonstrate the therapeutic efficacy of approaches that target and reduce Atxn1 expression in a non-allele-specific manner. However, studies using Atxn1

Identifiers

PMID32818920
PMCPMC7452125
OpenAlexW3045396005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.